Gastroparesis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Gastroparesis pipeline constitutes 8+ key companies continuously working towards developing 10+ Gastroparesis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Gastroparesis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastroparesis Market.

The Gastroparesis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Gastroparesis Pipeline Report: https://www.delveinsight.com/sample-request/gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Gastroparesis treatment therapies with a considerable amount of success over the years.
• Gastroparesis companies working in the treatment market are CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others, are developing therapies for the Gastroparesis treatment
• Emerging Gastroparesis therapies in the different phases of clinical trials are- CIN-102, Metoclopramide Nasal Spray, Tradipitant, IW-9179, TAK-954, NG101, CNSA-001, velusetrag, GM-611, Camicinal, PCS12852, and others are expected to have a significant impact on the Gastroparesis market in the coming years.
• In September 2025, CinDome Pharma, part of the CinRx portfolio focused on developing a safe, long-term treatment for gastroparesis, announced the completion of enrollment in the envision3D Phase 2 clinical trial of deudomperidone in adults with diabetic gastroparesis. Topline safety and efficacy results are expected in Q1 2026.
• In January 2025, Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced an update regarding the development of tradipitant. The company has accepted the FDA's offer for a hearing concerning the New Drug Application for tradipitant in the treatment of gastroparesis.

Gastroparesis Overview
Gastroparesis is a condition that affects the stomach's ability to empty its contents due to nerve damage caused by diabetes. The condition occurs when high blood sugar levels over time damage the vagus nerve, which controls the muscles of the stomach. This results in delayed gastric emptying, causing symptoms like nausea, vomiting, bloating, abdominal pain, and feeling full quickly after eating. It can lead to poor blood sugar control and malnutrition. Treatment focuses on managing blood sugar levels, dietary changes, and medications to improve stomach motility and relieve symptoms.

Get a Free Sample PDF Report to know more about Gastroparesis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Gastroparesis Drugs Under Different Phases of Clinical Development Include:
• CIN-102: CinDome Pharma, Inc.
• Metoclopramide Nasal Spray: Evoke Pharma
• Tradipitant: Vanda Pharmaceuticals
• IW-9179: Ironwood Pharmaceuticals
• TAK-954: Takeda
• NG101: Neurogastrx, Inc
• CNSA-001: PTC Therapeutics
• velusetrag: Theravance Biopharma
• GM-611: Chugai Pharma
• Camicinal: GlaxoSmithKline
• PCS12852: Processa Pharmaceuticals

Gastroparesis Route of Administration
Gastroparesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Gastroparesis Molecule Type
Gastroparesis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Gastroparesis Pipeline Therapeutics Assessment
• Gastroparesis Assessment by Product Type
• Gastroparesis By Stage and Product Type
• Gastroparesis Assessment by Route of Administration
• Gastroparesis By Stage and Route of Administration
• Gastroparesis Assessment by Molecule Type
• Gastroparesis by Stage and Molecule Type

DelveInsight's Gastroparesis Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Gastroparesis product details are provided in the report. Download the Gastroparesis pipeline report to learn more about the emerging Gastroparesis therapies
https://www.delveinsight.com/sample-request/gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Gastroparesis Therapeutics Market include:
Key companies developing therapies for Gastroparesis are - Bayer AG, Cipla Limited, Evoke Pharma, Pfizer Inc., Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Salix Pharmaceuticals, Inc., The Takeda Pharmaceutical, Teva Pharmaceutical, and others.

Gastroparesis Pipeline Analysis:
The Gastroparesis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Gastroparesis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastroparesis Treatment.
• Gastroparesis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gastroparesis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastroparesis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Gastroparesis drugs and therapies
https://www.delveinsight.com/sample-request/gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastroparesis Pipeline Market Drivers
• Growing prevalence of diabetes, Unmet medical need, Advancements in drug development, Improved awareness and diagnosis, Regulatory support for innovation, are some of the important factors that are fueling the Gastroparesis Market.

Gastroparesis Pipeline Market Barriers
• However, Limited effective treatment options, Challenges in drug development, Adverse side effects, High treatment costs, Regulatory challenges, and other factors are creating obstacles in the Gastroparesis Market growth.

Scope of Gastroparesis Pipeline Drug Insight
• Coverage: Global
• Key Gastroparesis Companies: CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others
• Key Gastroparesis Therapies: CIN-102, Metoclopramide Nasal Spray, Tradipitant, IW-9179, TAK-954, NG101, CNSA-001, velusetrag, GM-611, Camicinal, PCS12852, and others
• Gastroparesis Therapeutic Assessment: Gastroparesis current marketed and Gastroparesis emerging therapies
• Gastroparesis Market Dynamics: Gastroparesis market drivers and Gastroparesis market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.